spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Horizon Discovery and Fulcrum Therapeutics Form Collaboration for Novel CRISPR-Based Target Discovery in Genetic Diseases

Horizon Discovery Group

World leader in application of gene editing technologies announces collaboration with US-based Fulcrum Therapeutics

  • Horizon will deploy its CRISPR-based screening platform to identify novel targets for rare genetic diseases
  • The collaboration confirms Horizon’s role as a preferred partner not only for established biotechnology and pharmaceutical companies, but also for start-ups
  • The initial programme consists of two projects with the potential for additional future projects
Cambridge, UK, 6 September 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announced a new collaboration with Fulcrum Therapeutics Inc., (“Fulcrum”), a US-based firm founded in July 2016 by Third Rock Ventures. The collaboration will utilize Horizon’s world-leading CRISPR-based screening platform to identify novel targets for regulating gene expression. The programme will initially focus on genetic diseases where no effective treatment options currently exist.

Horizon’s CRISPR-based screening platform, sophisticated bioinformatics, and cell line libraries provide a novel and highly efficient way to examine the regulation of genes and their role in disease. In this collaboration, Horizon will apply its platform and extensive know-how to identify novel gene regulation targets for further exploration by Fulcrum for the development of next-generation therapies.

The work will be engaged under a Full-time Equivalent (FTE) plus consumables model in a programme expected to run between five and seven months. Fulcrum has chosen Horizon as its preferred CRISPR-based screening platform service provider, and there is potential for further screens to identify targets for additional rare diseases after this initial programme.

Dr. Darrin Disley, Chief Executive Officer, Horizon Discovery commented, “CRISPR-based screening promises to be a powerful tool for the identification of novel targets and the collaboration with Fulcrum demonstrates the potential for this technology to be used in areas outside of oncology.” He continued: “This partnership confirms Horizon’s role as a preferred partner not only for established biotechnology and pharmaceutical companies, but also for start-ups looking for long-term collaborations rather than having to build in-house capabilities.”

Robert Gould, Ph.D. President and Chief Executive Officer, Fulcrum Therapeutics, commented, “Horizon’s reputation in gene editing and its applications, including CRISPR-based screening, is unparalleled. It was natural for Fulcrum to turn to Horizon as a long-term partner. With their deep scientific expertise, and with a broad IP portfolio underpinning their work, we are confident in a productive and exciting collaboration.”
phone +44 (0)1223 655 580
web www.horizondiscovery.com/
email 7100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL
 
Print this page
Send to a friend
   
spacer
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>


White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

Industry Events

BioProcess International West

19-22 March 2018,

BioProcess International West (BPI West) is the leading phase-based bioprocessing event for advancing promising biologics towards commercial success.  Join 850+ global scientists and key decision makers at our upcoming meeting, held March 19-22, 2018 in San Francisco, CA. 
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement